

swedenBIO

Annual General Meeting 2006

Lund, June 1st



SwedenBIO Annual General Meeting 2006

10.00-13.00 From Idea to Product

10.00-10.20 Welcome and introduction

10.20-10.30 Welcome to Lund and Lund University
Allan Larsson, Chairman of the Board Lund University

10.30-10.50 Combining academic research with entrepreneurship Professor. Carl Borrebaeck, Lund University

10.50-11.10 How attract VC and financing to life science? Ways forward.
Claes de Neergaard, CEO Industrifonden

11.10-12.20 How create products from ideas? Four leading Nordic companies present their perspective
-Michael Wolff Jensen, CFO Life Cycle Pharma
-Peter Buhl-Jensen, CEO Topotarget
-Sven Andréasson, CEO Active Biotech
-Daniel Spasic, CEO Trial Form Support

12.20-13.00 Scandinavia as an engine of innovation and value creation – Big Pharma perspective
-Dr Theodore R. Koziol, Ph.D.VP Licensing and Business Development and Head, Regional Licensing Wyeth Pharmaceuticals

13.00-14.00 Lunch

14.00-15.00 SwedenBIO Annual General Meeting

15.00-15.30 Coffee

15.30-17.30 Parallel workshops by working groups

Science and business track:

- The Strategy Program & IMI– new support for the Swedish Life Science Industry**
Katarina Nordqvist, Vinnova
- Financing and Innovation Trends – The YIC Status: a catalyst for growing Life Science companies**
Per-Erik Sandlund, CEO SwedenBIO and Mats Berggren, SwedenBIO

-IP and Clinical Trials track:

- IP as a tool to secure value – dos and don'ts**
Staffan Wilow, CEO Af Petersens
- How can the EMEA SME-office support biotechnology companies?**
Melanie Carr, Head of EMEAs SME-office

17.30-21.00 Cocktail and Dinner at Lundia Hotel

Top Three Swedish Biotech Clusters Around Large Universities

Gothenburg


- 14 percent of Swedish biotech companies

Academia	Firm sample
<ul style="list-style-type: none">• Göteborg University• Sahlgrenska• Chalmers	<ul style="list-style-type: none">• AstraZeneca• Biovitrum• Carlsson Res.• Cellartis• Vitrolife• Nobel Biocare

Lund - Malmö

- 15 percent of Swedish biotech companies
- Swedish part of *Medicon Valley*

Academia	Firm sample
<ul style="list-style-type: none">• Lund University• Malmö University	<ul style="list-style-type: none">• Active Biotech• Alligator• BioInvent• Cellavision




Stockholm - Uppsala

- 54 percent of Swedish biotech companies
- Major players in Uppsala, Stockholm and Södertälje/Strängnäs

Academia	Firm sample
<ul style="list-style-type: none">• Karolinska Institute• Uppsala University• Stockholm University• Royal Institute of Technology (KTH)• SLU	<ul style="list-style-type: none">• AstraZeneca• GE Healthcare• Affibody• Biacore• Biovitrum• Gyros• Karo Bio• Medivir• Neuronova• Orexo• Phadia Diagnostics• Q-Med


Our Focus - Swedish Biotechnology – A National Agenda for Growth” (NBA)

Success factors




**Recommendations from 70 leading biotech CEOs and investors
”Biotechnology in Sweden – A National Agenda for Growth”**

SwedenBIO represents a broad Swedish Life Science industry – We are today 110 companies behind this message! We are becoming more every year !!



Working Groups and SwedenBIO Staff have complementary roles and functions for efficient advocacy work-Strong member influence



Roles and function:

Working Groups:

- Decide and communicate goals and direction based on industry need (Chairman)
- Provide expertise and experience (members)
- Annual presentation to Board (Chairman / members)
- Presentations at: CEO Summit, Annual General Meeting, webportal

SwedenBIO staff:

- Provide advocacy platform and infrastructure (CEO) Facilitate processes (Coordinator)
- Support realization of goals and activities

In 2006 SwedenBIO will focus its efforts on five clearly defined objectives

